## Disclosure Statement

**A Joint Working Project between Bristol-Myers Squibb Pharmaceutical Limited ("BMS") and North West Coast Academic Health Science Network; Innovation Agency ("AHSN")**

<table>
<thead>
<tr>
<th>Name of project</th>
<th><strong>Embedding new ways of working to reduce Atrial Fibrillation (AF) related strokes in the North West Coast</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Overview</td>
<td>North West Coast Academic Health Science Network; Innovation Agency (&quot;AHSN&quot;) has identified the need to embed new ways of working to reduce Atrial Fibrillation related strokes for patients in the North West Coast. The primary aim of the project is to prevent AF related strokes by driving the implementation of project initiatives which will be designed to support citizens, patients and clinicians increase their awareness of and reduce the risk of AF related stroke.</td>
</tr>
</tbody>
</table>
| Project objectives | The project aims to deliver four key objectives:  
  - Increasing awareness and educating citizens on the link between AF and Stroke,  
  - Support local healthcare teams across GP practices to improve the quality of care, management and outcomes for patients at risk of, or who have suffered an AF related stroke.  
  - Support patients diagnosed with AF to proactively manage their own care  
  - Increasing the detection of patients with AF |
| Patient benefits | Citizen and patient benefits may include but are not limited to:  
  - Increased awareness of the signs and symptoms of Atrial Fibrillation and the associated increased risk of stroke, enabling citizens to proactively manage any health concerns.  
  - A reduction in their risk of stroke through increased a  
  - Increased patient support to manage their AF related health condition and lifestyle following a confirmed diagnosis  
  - Improvements in patient experience and outcomes for those patients who have a confirmed diagnosis of AF. |
| Stakeholders | • North West Coast Academic Health Science Network; Innovation Agency ("AHSN")  
• Bristol Myers Squibb Pharmaceuticals Limited ("BMS") who is entering into the Agreement on its own behalf and for the benefit of Pfizer Limited (the **Alliance Partner** |
| Timelines | The project is scheduled to start on 3rd September 2018 and last for a 9 month period to 3rd June 2019 |